Organic Letters
Letter
(5) (a) Hay, J. E.; Haynes, L. J. J. Chem. Soc. 1958, 2231−2238.
(b) Rousseau, C.; Martin, O. R. Tetrahedron: Asymmetry 2000, 11,
409−412.
(6) (a) Martin, O. R. Tetrahedron Lett. 1985, 26, 2055−2058.
(b) Martin, O. R.; Hendricks, C. A. V.; Deshpande, P. P.; Cutler, A. B.;
Kane, S. A.; Rao, S. P. Carbohydr. Res. 1990, 196, 41−58. (c) Verlhac,
(27) For monographs on fluorine and medicinal chemistry, see:
́ ́
(a) Begue, J.-P.; Bonnet-Delpon, D. Bioorganic and Medicinal
Chemistry of Fluorine; John Wiley and Sons: New York, 2008.
(b) Ojima, I. Fluorine in Medicinal Chemistry and Chemical Biology;
Wiley-Blackwell: Chichester, 2009.
(28) For a recent review on fluorinated carbohydrates, see: Leclerc,
E.; Pannecoucke, X.; Ethev
Rev. 2013, 42, 4270−4283.
(29) For recent contributions on impact of fluorine on carbohydrates
behavior, see: (a) Bucher, C.; Gilmour, R. Angew. Chem., Int. Ed. 2010,
̀
e-Quelquejeu, M.; Sollogoub, M. Chem. Soc.
P.; Leteux, C.; Toupet, L.; Veyrier
11−20.
̀
es, A. Carbohydr. Res. 1996, 291,
(7) Martin, O. R. Carbohydr. Res. 1987, 171, 211−222.
(8) Girard, N.; Rousseau, C.; Martin, O. R. Tetrahedron Lett. 2003,
44, 8971−8974.
49, 8724−8728. (b) N’Go, I.; Golten, S.; Arda, A.; Canada, J.; Jimenez-
̃
Barbero, J.; Linclau, B.; Vincent, S. P. Chem. - Eur. J. 2014, 20, 106−
112. (c) Aiguabella, N.; Holland, M. C.; Gilmour, R. Org. Biomol.
Chem. 2016, 14, 5534−5538.
(9) Mayr, H.; Patz, M. Angew. Chem., Int. Ed. Engl. 1994, 33, 938−
957.
(10) (a) Mukherjee, D.; Sarkar, S. K.; Chowdhury, U. S.; Taneja, S.
C. Tetrahedron Lett. 2007, 48, 663−667. (b) Wacker, O.; Fritz, H.
Helv. Chim. Acta 1967, 50, 2481−2490.
(11) Olah, G. A.; Prakash, G. K. S.; Molnar, A.; Sommer, J.
Superacids, 2nd ed.; John Wiley and Sons: New York, 2009.
(12) Olah, G. A.; Klumpp, D. A. Superelectrophiles and Their
Chemistry; John Wiley and Sons: New York, 2008.
(13) Naredla, R. R.; Klumpp, D. Chem. Rev. 2013, 113, 6905−6948.
(14) For recent examples of intramolecular arylation and the
cyclization/fluorination process based on superelectrophilic activation,
see: (a) Li, A.; Kindelin, P. J.; Klumpp, D. A. Org. Lett. 2006, 8, 1233−
1236. (b) Klumpp, D. A.; Zhang, Y.; O’Connor, M. J.; Esteves, P. M.;
de Almeida, L. S. Org. Lett. 2007, 9, 3085−3088. (c) Boblak, K. N.;
Klumpp, D. A. J. Org. Chem. 2014, 79, 5852−5857. (d) Vardelle, E.;
Gamba-Sanchez, D.; Martin-Mingot, A.; Jouannetaud, M.-P.;
Thibaudeau, S.; Marrot, J. Chem. Commun. 2008, 44, 1473−1475.
(e) Compain, G.; Martin-Mingot, A.; Frapper, G.; Bachmann, C.;
Jouannetaud, M.-P.; Thibaudeau, S. Chem. Commun. 2012, 48, 5877−
5879. (f) Compain, G.; Bonneau, C.; Martin-Mingot, A.; Thibaudeau,
S. J. Org. Chem. 2013, 78, 4463−4472. (g) Liu, F.; Martin-Mingot, A.;
Jouannetaud, M.-P.; Zunino, F.; Thibaudeau, S. Org. Lett. 2010, 12,
868−871.
(30) Fluoroamines are now regarded as tools of high interest in
medicinal chemistry: (a) Morgenthaler, M.; Schweizer, E.; Hoffmann-
Roder, F.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer,
H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.;
Muller, K. ChemMedChem 2007, 2, 1100−1115. (b) Hagmann, W. H.
J. Med. Chem. 2008, 51, 4359−4369.
(31) Airoldi, C.; D’Orazio, G.; Richichi, B.; Guzzi, C.; Baldoneschi,
V.; Colombo, L.; Salmona, M.; Nativi, C.; Nicotra, F.; La Ferla, B.
Chem. - Asian J. 2016, 11, 299−309.
(15) Martin, A.; Arda, A.; Des
Barbero, J.; Thibaudeau, S.; Bler
(16) For data on HF/SbF5 composition, see: Culmann, J.-C.;
Fauconet, M.; Jost, R.; Sommer, J. New J. Chem. 1999, 23, 863−867
and references cited therein.
́
ire,
́
J.; Mingot, A.; Probst, N.; Jimenez-
́
iot, Y. Nat. Chem. 2016, 8, 186−191.
(17) As a side reaction in the synthesis of a 2-O-benzylglucofuranosyl
fluoride derivative, a similar cyclization of a 2-O-benzylglucofuranoside
in HF has been mentioned: Miethchen, R.; Gabriel, T. J. Fluorine
Chem. 1994, 67, 11−15.
(18) For more details, see the SI.
(19) Dutta, S.; Basak, A.; Dasgupta, S. Bioorg. Med. Chem. 2009, 17,
3900−3908.
(20) Olah, G. A.; Burrichter, A.; Rasul, G.; Surya Prakash, G. K.;
Hachoumy, M.; Sommer, J. J. Am. Chem. Soc. 1996, 118, 10423−
10428.
(21) McLain, S. E.; Benmore, C. J.; Siewenie, J. E.; Urquidi, J.;
Turner, J. F. C. Angew. Chem., Int. Ed. 2004, 43, 1952−1955 and
references cited therein.
(22) For a review on sugar−azacycle hybrids, see: Tietze, L. F.; Bell,
H. P.; Chandrasekhar, S. Angew. Chem., Int. Ed. 2003, 42, 3996−4028.
(23) For multistep synthesis of bioactive analogues, see: (a) Reddy,
G.; Vankar, Y. D. Angew. Chem., Int. Ed. 2005, 44, 2001−2004.
(b) Aydillo, C.; Navo, C. D.; Busto, J. H.; Corzana, F.; Zurbano, M.
M.; Avenoza, A.; Peregrina, J. M. J. Org. Chem. 2013, 78, 10968−
10977.
(24) For an elegant synthesis of a similar octahydropyrano[3,2-b]
pyridine-6,7,8-triol derivative, a key intermediate in the synthesis of
mannosidase inhibitor natural product swainsonine, see: Fleet, G. W.
J.; Gough, M. J.; Smith, P. W. Tetrahedron Lett. 1984, 25, 1853−1856.
́
(25) Huang, M.; Retailleau, P.; Bohe, L.; Crich, D. J. Am. Chem. Soc.
2012, 134, 14746−14789.
(26) The modest yields probably arise from a partial degradation of
the product during the purification process.
D
Org. Lett. XXXX, XXX, XXX−XXX